Roche ups full-year guidance as 9-month sales surge 10%

16 October 2019

Swiss pharma giant Roche (ROG: SIX) this morning released financial results for the first nine months of 2019, showing that group sales increased 10% to 46.07 billion Swiss francs ($46.16 billion) at constant exchange rates and 9% in Swiss francs, due to new products.

Pharmaceuticals Division sales were up 12% at 36.56 billion francs, driven by high demand for recently launched medicines. Diagnostic division sales at 9.51 billion francs were up 4%.

Roche shares, which have climbed about 16% so far this year, rose as much as 1% in early Zurich trading. Roche has not released any earnings figures.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK